6-(3,5-Dichlorobenzoyl)-1-[(2,6-difluoropyridin-4-yl)methyl]-5-propan-2-ylpyrimidine-2,4-dione | 1006300-88-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(3,5-Dichlorobenzoyl)-1-[(2,6-difluoropyridin-4-yl)methyl]-5-propan-2-ylpyrimidine-2,4-dione
• CAS: 1006300-88-4
• 化学式: C₂₀H₁₅Cl₂F₂N₃O₃
• 分子量: 454.26
• InChiKey: HQHLCZRLXKSPRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  79.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-(3,5-Dichloro-benzoyl)-5-isopropyl-1H-pyrimidine-2,4-dione 、 (2,6-Difluoropyridin-4-yl)methyl methanesulfonate 在 potassium carbonate 、 lithium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-(3,5-Dichlorobenzoyl)-1-[(2,6-difluoropyridin-4-yl)methyl]-5-propan-2-ylpyrimidine-2,4-dione
  参考文献：
  名称：

  Novel HIV reverse transcriptase inhibitors

  摘要：

  这项发明涉及到以下化合物的公式(I)、(II)或(III)： 或其药用可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。

  公开号：

  US20080070920A1

文献信息

• NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Guo Hongyan

  公开号：US20100034827A1

  公开（公告）日：2010-02-11

  The invention is related to compounds of Formula (I), (II), or (III); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及公式(I)、(II)或(III)的化合物；或其药学上可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这些化合物的组合物以及包括给予这些化合物的治疗方法。
• US8106064B2
  申请人：——

  公开号：US8106064B2

  公开（公告）日：2012-01-31
• [EN] NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS<br/>[FR] INHIBITEURS INÉDITS DE LA TRANSCRIPTASE INVERSE DU VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2008016522A2

  公开（公告）日：2008-02-07

  [EN] The invention is related to com ounds of Formula (I), (II), or (III); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.
  [FR] L'invention concerne des composés de formule (I), (II) ou (III), ou encore un de leurs sels, solvates, esters et/ou phosphonates, acceptables d'un point de vue pharmaceutique, des produits contenant lesdits composés et des procédés thérapeutiques comprenant l'administration desdits composés.
• [EN] COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE INFECTION PAR MLV, ET PRÉVENTION ET TRAITEMENT DE MALADIES CAUSÉES PAR MLV
  申请人：UNIV EMORY

  公开号：WO2011041512A2

  公开（公告）日：2011-04-07

  Compositions and methods for inhibiting infection by XMRV or other MLV are disclosed. Also disclosed are methods for treating cancers resulting from infection by XMRV or other MLV, and for preventing such cancers. The anti- XMRV/anti-MLV compounds are predominantly integrase inhibitors, such as globoidnan A, L-000870812, S/GSK1349572, S/GSK1265744, Raltegravir and Elvitegravir, and also reverse transcriptase inhibitors AZT, tenofovir, and tenofovir DF. The compounds are also useful for treating chronic fatigue syndrome or other diseases with neuroimmune symptoms resulting from an infection by XMRV or other MLV. The compositions can also include other therapeutic agents known for treating prostate cancer, breast cancer, lymphomas, and leukemias, such as anti-androgenic agents, radioisotopes, and conventional anti-cancer compounds.
• Novel HIV reverse transcriptase inhibitors
  申请人：Guo Hongyan

  公开号：US20080070920A1

  公开（公告）日：2008-03-20

  The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  这项发明涉及到以下化合物的公式(I)、(II)或(III)： 或其药用可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。